NASDAQ:ALIM Alimera Sciences (ALIM) Stock Forecast, Price & News $2.64 +0.06 (+2.33%) (As of 05/26/2023 03:59 PM ET) Add Compare Share Share Today's Range$2.50▼$2.6850-Day Range$1.35▼$2.6452-Week Range$1.30▼$7.92Volume64,100 shsAverage Volume386,104 shsMarket Capitalization$19.54 millionP/E RatioN/ADividend YieldN/APrice Target$5.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Alimera Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside121.0% Upside$5.83 Price TargetShort InterestHealthy0.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 9 Articles This WeekInsider TradingAcquiring Shares$2.38 M Bought Last QuarterProj. Earnings Growth193.75%From $0.16 to $0.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.65 out of 5 starsMedical Sector95th out of 1,010 stocksPharmaceutical Preparations Industry35th out of 494 stocks 3.3 Analyst's Opinion Consensus RatingAlimera Sciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.83, Alimera Sciences has a forecasted upside of 121.0% from its current price of $2.64.Amount of Analyst CoverageAlimera Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.44% of the float of Alimera Sciences has been sold short.Short Interest Ratio / Days to CoverAlimera Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alimera Sciences has recently decreased by 10.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlimera Sciences does not currently pay a dividend.Dividend GrowthAlimera Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALIM. Previous Next 2.9 News and Social Media Coverage News SentimentAlimera Sciences has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Alimera Sciences this week, compared to 3 articles on an average week.Search Interest9 people have searched for ALIM on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows1 people have added Alimera Sciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alimera Sciences insiders have bought 660.36% more of their company's stock than they have sold. Specifically, they have bought $2,383,232.00 in company stock and sold $313,434.00 in company stock.Percentage Held by Insiders12.90% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 24.58% of the stock of Alimera Sciences is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Alimera Sciences are expected to grow by 193.75% in the coming year, from $0.16 to $0.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alimera Sciences is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alimera Sciences is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Alimera Sciences (NASDAQ:ALIM) StockAlimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.Read More Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ALIM Stock News HeadlinesMay 25, 2023 | finance.yahoo.comAlimera (ALIM) Completes Enrollment in Eye Disease StudyMay 25, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM)May 29, 2023 | Investor Place Media (Ad)Disturbing Truth About Biden's New Program To Seize Your CashA former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.May 24, 2023 | finance.yahoo.comAlimera Completes Recruitment for its Landmark NEW DAY StudyMay 23, 2023 | finance.yahoo.comAlimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain StockMay 23, 2023 | americanbankingnews.comHC Wainwright Weighs in on Alimera Sciences, Inc.'s Q4 2024 Earnings (NASDAQ:ALIM)May 23, 2023 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Given New $5.00 Price Target at HC WainwrightMay 22, 2023 | americanbankingnews.comAlimera Sciences, Inc. (NASDAQ:ALIM) Director Adam Morgan Buys 1,401,901 SharesMay 29, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 20, 2023 | msn.com4 Analysts Have This to Say About Alimera SciencesMay 19, 2023 | finance.yahoo.comAlimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to YutiqMay 18, 2023 | finance.yahoo.comQ1 2023 Alimera Sciences Inc Earnings CallMay 18, 2023 | barrons.comEyePoint Pharmaceuticals Announces Sale of YUTIQ(R) to Alimera Sciences, Inc. for $82.5 Million Cash Plus RoyaltiesMay 18, 2023 | bizjournals.comEyePoint licenses inflammation drug to Atlanta firm for $82.5MMay 18, 2023 | msn.comAlimera Snaps Up Rights for Yutiq from EyePoint PharmaMay 18, 2023 | marketwatch.comAlimera Sciences Shares Rise 22% After Buying U.S. Yutiq Rights From EyePointMay 18, 2023 | investorplace.comWhy Is Alimera Sciences (ALIM) Stock Up 21% Today?May 18, 2023 | msn.comEyePoint Pharma Offloads Its Commercially-Available Eye Implant For $82.5M Plus RoyaltiesMay 18, 2023 | finance.yahoo.comEyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus RoyaltiesMay 18, 2023 | marketwatch.comAlimera Sciences Buys U.S. Commercial Rights to Chronic Uveitis Treatment YutiqMay 18, 2023 | msn.comAlimera jumps 48% on deal with EyePoint for eye disorder therapy YutiqMay 18, 2023 | finance.yahoo.comAlimera Acquires U.S. Commercial Rights to YUTIQ®May 17, 2023 | msn.comHC Wainwright & Co. Reiterates Alimera Sciences (ALIM) Buy RecommendationMay 17, 2023 | finance.yahoo.comAlimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ETMay 17, 2023 | americanbankingnews.comBrokers Set Expectations for Alimera Sciences, Inc.'s Q1 2024 Earnings (NASDAQ:ALIM)May 17, 2023 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Now Covered by Analysts at StockNews.comMay 17, 2023 | americanbankingnews.comAlimera Sciences, Inc. (NASDAQ:ALIM) Sees Large Decline in Short InterestSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ALIM Company Calendar Last Earnings10/27/2021Today5/29/2023Next Earnings (Estimated)7/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALIM CUSIPN/A CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees145Year Founded2003Price Target and Rating Average Stock Price Forecast$5.83 High Stock Price Forecast$8.00 Low Stock Price Forecast$4.50 Forecasted Upside/Downside+121.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E Ratio16.50 P/E GrowthN/ANet Income$-18,110,000.00 Net Margins-30.69% Pretax Margin-30.64% Return on EquityN/A Return on Assets-37.66% Debt Debt-to-Equity RatioN/A Current Ratio2.52 Quick Ratio2.43 Sales & Book Value Annual Sales$54.13 million Price / Sales0.36 Cash FlowN/A Price / Cash FlowN/A Book Value($5.72) per share Price / Book-0.46Miscellaneous Outstanding Shares7,400,000Free Float6,450,000Market Cap$19.54 million OptionableOptionable Beta1.38 Social Links Key ExecutivesRichard S. EiswirthPresident, Chief Executive Officer & DirectorPhilip John AshmanCOO & SVP-Commercial Operations EuropeRussell L. SkibstedChief Financial Officer & Senior Vice PresidentChristopher S. VisickSecretary, Vice President & General CounselDavid DyerChief Retina SpecialistKey CompetitorsZynerba PharmaceuticalsNASDAQ:ZYNEGeoVax LabsNASDAQ:GOVXIndaptus TherapeuticsNASDAQ:INDPHumanigenNASDAQ:HGENNeuroSense TherapeuticsNASDAQ:NRSNView All CompetitorsInsidersAdam MorganBought 1,401,901 shares on 5/17/2023Total: $2.38 M ($1.70/share)Alto Investors Lp PaloSold 200,919 sharesTotal: $313,433.64 ($1.56/share)View All Insider Transactions ALIM Stock - Frequently Asked Questions Should I buy or sell Alimera Sciences stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALIM shares. View ALIM analyst ratings or view top-rated stocks. What is Alimera Sciences' stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month price objectives for Alimera Sciences' shares. Their ALIM share price forecasts range from $4.50 to $8.00. On average, they anticipate the company's stock price to reach $5.83 in the next year. This suggests a possible upside of 121.0% from the stock's current price. View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts. How have ALIM shares performed in 2023? Alimera Sciences' stock was trading at $2.71 at the start of the year. Since then, ALIM shares have decreased by 2.6% and is now trading at $2.64. View the best growth stocks for 2023 here. When is Alimera Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023. View our ALIM earnings forecast. How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) posted its earnings results on Wednesday, October, 27th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.08. The biopharmaceutical company earned $12.15 million during the quarter, compared to analysts' expectations of $12.30 million. During the same quarter in the prior year, the company earned ($0.12) earnings per share. When did Alimera Sciences' stock split? Alimera Sciences shares reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Rick Eiswirth's approval rating as Alimera Sciences' CEO? 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB). What is Alimera Sciences' stock symbol? Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM." How do I buy shares of Alimera Sciences? Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alimera Sciences' stock price today? One share of ALIM stock can currently be purchased for approximately $2.64. How much money does Alimera Sciences make? Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $19.54 million and generates $54.13 million in revenue each year. The biopharmaceutical company earns $-18,110,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. How many employees does Alimera Sciences have? The company employs 145 workers across the globe. How can I contact Alimera Sciences? Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744. This page (NASDAQ:ALIM) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.